{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:46:27Z","timestamp":1775162787435,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.esmoop.2022.100633","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T17:46:15Z","timestamp":1669657575000},"page":"100633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pooled safety analysis from phase III studies of trifluridine\/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"E.","family":"Van Cutsem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hochster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.H.","family":"Ilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-T.","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Benhadji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Makris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2022.100633_bib1","first-page":"571","article-title":"A\u00a0novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA","volume":"25","author":"Emura","year":"2004","journal-title":"Int J Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100633_bib2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100633_bib3","first-page":"545","article-title":"A\u00a0novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells","volume":"13","author":"Emura","year":"2004","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.esmoop.2022.100633_bib4","series-title":"LONSURF\u00ae (trifluridine and tipiracil) tablets [prescribing information]","year":"2019"},{"issue":"20","key":"10.1016\/j.esmoop.2022.100633_bib5","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2022.100633_bib6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2022.100633_bib7","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2015.65.1554","article-title":"Renal dysfunction has statistically and clinically significant deleterious effects on anticancer drug safety","volume":"34","author":"Launay-Vacher","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100633_bib8","first-page":"1057","article-title":"Chemotherapy dosing in the setting of liver dysfunction","volume":"19","author":"Eklund","year":"2005","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100633_bib9","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2022.100633_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","article-title":"Hepatotoxicity of chemotherapy","volume":"6","author":"King","year":"2001","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.esmoop.2022.100633_bib11","first-page":"3461","article-title":"Management of hepatotoxicity of chemotherapy and targeted agents","volume":"11","author":"Mudd","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2022.100633_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100633_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2016.04.009","article-title":"A\u00a0multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)","volume":"62","author":"Bando","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100633_bib14","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clcc.2016.04.004","article-title":"TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing surveillance study","volume":"15","author":"Yoshino","year":"2016","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100633_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3747\/co.26.5107","article-title":"Real-world use of trifluridine\/tipiracil for patients with metastatic colorectal cancer in Canada","volume":"26","author":"Samawi","year":"2019","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100633_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10147-017-1220-0","article-title":"Feasibility and effectiveness of trifluridine\/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands","volume":"23","author":"Kwakman","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100633_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","article-title":"Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100633_bib18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12885-016-2491-y","article-title":"Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study","volume":"16","author":"Kasi","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100633_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-020-04129-6","article-title":"Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD\/TPI plus bevacizumab: a retrospective study","volume":"86","author":"Nose","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100633_bib20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/bcp.13856","article-title":"Open-label study to evaluate trifluridine\/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment","volume":"85","author":"Saif","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2022.100633_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00280-021-04308-z","article-title":"A\u00a0phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine\/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment","volume":"88","author":"Saif","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100633_bib22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2022.100633_bib23","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100633_bib24","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.esmoop.2022.100633_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2022.100633_bib26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"10.1016\/j.esmoop.2022.100633_bib27","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2217\/fon-2018-0147","article-title":"Trifluridine\/tipiracil: an emerging strategy for the management of gastrointestinal cancers","volume":"14","author":"Peeters","year":"2018","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2022.100633_bib28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"issue":"4","key":"10.1016\/j.esmoop.2022.100633_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.esmoop.2022.100633_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2022.100633_bib32","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ctrv.2015.06.001","article-title":"TAS-102, a novel antitumor agent: a review of the mechanism of action","volume":"41","author":"Lenz","year":"2015","journal-title":"Cancer Treat Rev"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T09:26:34Z","timestamp":1718789194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2059702922002678"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100633","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pooled safety analysis from phase III studies of trifluridine\/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100633"}}